Skip to Content

Brineura FDA Approval History

FDA Approved: Yes (First approved April 27, 2017)
Brand name: Brineura
Generic name: cerliponase alfa
Dosage form: Injection
Company: BioMarin Pharmaceutical Inc.
Treatment for: CLN2 Disease

Brineura (cerliponase alfa) is an enzyme replacement therapy for the restoration of tripeptidyl peptidase-1 (TPP1) enzyme activity in patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), or TPP1 deficiency, a form of Batten disease.

Development Timeline for Brineura

DateArticle
Apr 27, 2017Approval FDA Approves Brineura (cerliponase alfa) for CLN2 Disease, a Form of Batten Disease
Sep  6, 2016BioMarin Announces Update to Brineura (cerliponase alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
Jul 27, 2016FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease, Form of Batten Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.